FDA approves eye drops that could replace your reading glasses

By Monica Athnasious

Published Dec 13, 2021 at 12:08 PM

Reading time: 2 minutes

25480

From diagnosing depression with a blood test to testing revolutionary brain implants capable of restoring a blind person’s eyesight, advancements in the medical world show no sign of slowing. The latest striking innovation in healthcare, as first reported by CBS News, is set to revolutionise the lives of glass wearers in the US.

After getting approved by the Food and Drug Administration (FDA) back in October 2021, the new medicine has made headlines again for hitting the market just this week. Introducing Vuity, the first eye drop remedy created to sharpen near vision. Said to improve vision for up to six to ten hours at a time from as little as one drop in each eye, the new treatment, developed by biopharmaceutical company AbbVie, was initially produced as an alternative method to treating presbyopia—more commonly known as age-induced blurry sight.

It is believed that more than 128 million Americans, specifically pertaining to those aged 40 and above, have the condition—the most prominent symptom of which involves difficulty in reading words up close. In a press release for Vuity, Michael Severino, vice chairman and president of AbbVie, stated, “Most adults cope with presbyopia, or difficulty with near vision as we age. Beginning around the age of 40, many find themselves using reading glasses, holding text further away, or even increasing the font size and lighting on screens to try to see more clearly.”

He continued by admitting how Vuity is a first-of-its-kind, once-daily eye drop that the company believes will change the way people and their eye doctors approach presbyopia. “The FDA approval of Vuity exemplifies our continued pursuit of innovative new treatments that push the boundaries of what’s possible in eye care,” he added. So, how does it work?

Well, the drops reportedly utilise the eye’s natural skill to reduce its pupil size. Doctor George Waring—the principal investigator of the drug’s clinical trial—told CBS, “Reducing the pupil size expands the depth of field or the depth of focus, and that allows you to focus at different ranges naturally.” Those in the clinical trial, consisting of 750 participants, were able to see three more lines (than they usually would) on their reading chart just 15 minutes after being administered a singular drop in each eye.

Want to get your hands on some? Well, as part of its press release for Vuity, AbbVie stated that the eye drops will cost you around $80 for a 30-day supply—the drops are currently only available via prescription and, as of now, not covered by insurance (and unlikely to be, as glasses are seen as the cheaper alternative).

Like with any new medical treatment, shortcomings are bound to arise as side effects listed by the company in the trial included red eyes and headaches. However, Waring told CBS that “this is something that we anticipate will be well tolerated long term, but this will be evaluated and studied in a formal capacity.” Such symptoms are an indication that Vuity is not an all-in-one solution.

Aside from these side effects, AbbVie also warns users against administering the drops if one is driving at night or engaging with activities planned in low-light conditions. The pharmaceutical company further noted that its product’s efficacy will vary depending on the patient; it is likely to be more successful in those with mild to intermediate cases of blurry vision and less effective in those over the age of 65.

All that being said, one happy candidate of the trial told CBS that the medicine is a “life changer.” Toni Wright, the participant in question, shared with the media outlet, “I would not need my readers as much, especially on the computer, where I would always need to have them on.”

Keep On Reading

By Abby Amoakuh

Chappell Roan faces backlash from TikTok moms for likening motherhood to hell

By Abby Amoakuh

John Lithgow fumbles JK Rowling question as Harry Potter TV show cast struggles with fan backlash

By Abby Amoakuh

BLACKPINK’s Lisa faces backlash after wearing civil rights icon Rosa Parks on her crotch at Met Gala

By Charlie Sawyer

From performing at Mother Teresa’s canonization to 10+ film roles, no one works as hard as Rita Ora’s agent

By Charlie Sawyer

Are digital ghosts and deepfakes of the dead threatening the way we grieve?

By Sam Davies

These scream queens walked so horror it girl Jenna Ortega could run

By Charlie Sawyer

Sabrina Carpenter accused of centering men on controversial album cover

By Abby Amoakuh

Who is Lauren Handy, the woman who kept the remains of five foetuses in her refrigerator?

By Fatou Ferraro Mboup

Kim Kardashian’s Paris $10 million heist: grandpa robbers tell all as trial begins

By Charlie Sawyer

Wednesday star Jenna Ortega reveals surprising dream role in recent interview

By Charlie Sawyer

UK women who miscarry could face home and phone searches following new anti-abortion police guidance

By Abby Amoakuh

Blake Lively faces backlash for calling herself Cherokee in resurfaced L’Oréal diversity ad

By Charlie Sawyer

Harry Potter star defends Tom Felton over his controversial comments on JK Rowling’s transphobia

By Charlie Sawyer

Why are today’s McDonald’s restaurants so dull and grey? Here’s what conspiracy theorists believe

By Charlie Sawyer

Donald Trump shares ignorant AI-generated video of what Gaza would look like under his rule

By Fatou Ferraro Mboup

Hannah Berner under fire for microaggressions in Megan Thee Stallion interview

By Charlie Sawyer

Trump grants white South Africans refuge after ending legal protections for Afghans facing deportation

By Fatou Ferraro Mboup

Here’s how the Trump administration has already worsened the humanitarian crisis in Sudan

By Abby Amoakuh

Celebrity Big Brother: JoJo Siwa’s partner Kath Ebbs turns off comments amid Chris Hughes romance rumours

By Abby Amoakuh

Kylie Jenner labelled as tone deaf for using private jet excessively during LA wildfires